Creatine monohydrate for lean mass, strength, and bone density in postmenopausal women: a systematic review and meta-analysis.
閉経後女性における除脂肪量、筋力、骨密度に対するクレアチンモノハイドレートの効果:系統的レビューとメタ分析 (機械翻訳の邦題)
記録の確認項目
- 研究デザイン
- メタ分析
- 対象
- ヒト
- 出版年
- 2026
- 出典
- doi.org
- 抄録の表示
- 表示あり
- 出版状態
- 有効な記録
- 状態確認日
- 2026/08/17
- 収集日
- 2026/08/04
- 鮮度
- 確認期限内
- 確認段階
- 自動処理
- 記録状態
- 公開
日本語要約(機械生成)
閉経後女性におけるクレアチン補給の効果を検討するため、無作為化プラセボ対照試験を系統的にレビューし、メタ分析を行った。7件の試験(計608名、平均年齢約62歳、期間12〜104週)を対象とした。その結果、クレアチン補給は除脂肪量を平均0.37kg増加させ、レッグプレス1RMを平均7.5kg向上させた。効果は1日5g以上のクレアチンとレジスタンストレーニングを併用した場合に認められ、1日3g以下でトレーニングなしでは効果がなかった。骨密度には変化がなかった。有害事象は軽度でプラセボと同等であり、腎機能への影響もなかった。クレアチン補給は閉経後女性において安全で、除脂肪量と筋力の改善に有効である可能性が示唆されたが、骨密度への効果は不明である。
この要約は公開抄録のみを根拠にAIが機械的に生成したものです。正確な内容は原文を確認してください。
抄録
Background: Menopause is accompanied by accelerated losses in muscle mass and strength and declining bone density. Whether creatine monohydrate benefits postmenopausal women are uncertain.Methods: We systematically reviewed randomized, placebo-controlled trials examining creatine supplementation, with or without resistance training (RT), in postmenopausal women. MEDLINE, Embase, Scopus, Web of Science, SPORTDiscus, and Cochrane CENTRAL were searched from 2000 to August 2025, supplemented by trial registries and reference-list screening. Eligible studies included postmenopausal women aged ≥40-45 years, intervention durations ≥6 weeks for primary analyses, and outcomes including DXA-derived lean mass, one-repetition maximum (1RM) strength, bone mineral density, physical function, and safety. Dual screening, duplicate extraction, and Cochrane RoB 2 assessment were performed. Random-effects meta-analysis used the Paule-Mandel estimator for τ² with Hartung-Knapp-Sidik-Jonkman adjustment. Heterogeneity (τ², I²), 95% prediction intervals, subgroup analyses by RT status, exploratory dose/duration meta-regression, small-study effects, and GRADE certainty were assessed.Results: Seven RCTs (n = 608 randomized; duration 12-104 weeks, median 38 weeks) enrolled postmenopausal women (mean age ≈ 62 y). Lean mass (k = 5; n = 338) favored creatine: mean difference (MD) + 0.37 kg (95% CI + 0.05 to + 0.69; I² = 25%; τ² = 0.01; 95% PI -0.10 to + 0.84). Leg-press 1RM (k = 3; n = 111) improved with creatine: MD + 7.5 kg (95% CI + 2.2 to + 12.8; I² = 0%). Benefits were evident when creatine ≥ 5 g·day⁻¹ was combined with RT; trials using ≤ 3 g·day⁻¹ without RT showed no measurable effect. Bone density was unchanged overall. Adverse events were mild and similar to placebo; renal indices were unchanged. Risk of bias was mostly "some concerns;" one large, preregistered, double-blind RCT was at low risk.Conclusions: In postmenopausal women, creatine, particularly ≥ 5 g·day⁻¹ with RT, yields small but meaningful gains in lean mass and strength without evidence of harm. Effects on bone density remain unclear.Registration: This review was not prospectively registered. De-identified data and supplementary materials were deposited on OSF after completion of the analysis (DOI: 10.17605/OSF.IO/BVTRZ).
MeSH
DOI 10.1080/15502783.2026.2668435
PMID 42141930
原文・出典を見る →